Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
Portfolio Pulse from
Nexalin Technology has received IRB approval from UCSD for clinical trials of its HALO Clarity headset, aimed at treating mTBI and PTSD.
February 18, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology received IRB approval from UCSD for clinical trials of its HALO Clarity headset, which could enhance its market position in treating mTBI and PTSD.
The IRB approval is a significant regulatory milestone for Nexalin, allowing it to proceed with clinical trials. This could lead to positive outcomes in the treatment of mTBI and PTSD, potentially increasing demand for its products and positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100